Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560855 | 0.82 | PPARA (0.41) | PPARAALDH1A1LMNAACACB | |
| SCHEMBL788296 | 0.81 | SMN1; SMN2 (0.50) | ALDH1A1LMNAACACBEBPSIGMAR1 | |
| SCHEMBL19644362 | 0.81 | SMN1; SMN2 (0.50) | ALDH1A1LMNAACACBEBPSIGMAR1 | |
| SCHEMBL10455828 | 0.81 | LMNA (0.39) | PPARAALDH1A1LMNAACACBEBP | |
| SCHEMBL9614864 | 0.80 | SMN1; SMN2 (0.48) | ALDH1A1LMNAACACBEBPSIGMAR1 | |
| SCHEMBL6027401 | 0.78 | NR5A1 (0.51) | S1PR1 | |
| SCHEMBL10454958 | 0.77 | SMN1; SMN2 (0.46) | PPARAALDH1A1LMNAACACBSMN1; SMN2 | |
| SCHEMBL9575718 | 0.77 | ALDH1A1 (0.39) | PPARAALDH1A1LMNAACACBEBP | |
| SCHEMBL9575749 | 0.77 | ACACB (0.38) | PPARAALDH1A1LMNAACACBEBP | |
| SCHEMBL3975354 | 0.77 | THRA (0.38) | ALDH1A1LMNAACACBEBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330295-B1 | PHOTOPOLYMERIZATION INITIATOR COMPOSITION, ACTIVE ENERGY RAY-CURABLE COMPOSITION, AND CURED PRODUCT | FUJIFILM CORP (JP) | 2019-08-21 | — | — | EP | disclosed |
| EP-3330295-A1 | PHOTOPOLYMERIZATION INITIATOR COMPOSITION, ACTIVE ENERGY RAY-CURABLE COMPOSITION, AND CURED PRODUCT | FUJIFILM Corporation (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-20180148519-A1 | PHOTOPOLYMERIZATION INITIATOR COMPOSITION, ACTIVE ENERGY RAY-CURABLE COMPOSITION, AND CURED PRODUCT | FUJIFILM CORPORATION (JP) | 2018-05-31 | — | — | US | disclosed |
| EP-1451615-B1 | METHOD FOR MODIFYING THE SURFACE OF BIOMEDICAL ARTICLES | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-6878399-B2 | Method for modifying the surface of biomedical articles | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| EP-1451615-A1 | METHOD FOR MODIFYING THE SURFACE OF BIOMEDICAL ARTICLES | Novartis AG (CH) | 2004-09-01 | — | — | EP | disclosed |
| US-20030219533-A1 | Method for modifying the surface of biomedical articles | NOVARTIS AG (CH) | 2003-11-27 | — | — | US | disclosed |
| WO-2003042724-A1 | METHOD FOR MODIFYING THE SURFACE OF BIOMEDICAL ARTICLES | NOVARTIS AG (CH) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148519-A1 | PHOTOPOLYMERIZATION INITIATOR COMPOSITION, ACTIVE ENERGY RAY-CURABLE COMPOSITION, AND CURED PRODUCT | PARP1, PARP9, PARP4 | PPARA 3522/4885MMP1 2635/4885MMP9 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.